Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
LipoScience shares rise on 1st day of trading
Friday - 1/25/2013, 11:41am EST
NEW YORK (AP) - Shares of LipoScience are up on their first day of trading, but the initial public offering of the cholesterol diagnostic test maker priced well below expectations.
The Raleigh, N.C., company sold 5 million shares for $9 each. Earlier this month LipoScience said it expected its IPO to price at $13 to $15 per share. On Thursday it lowered that range to $9 to $10 per share.
The shares rose 7 percent to $9.63 in midday trading Friday while the broader markets edged higher.
LipoScience Inc. makes a diagnostic test for LDL or "bad" cholesterol that is designed to assess cardiovascular disease risk.
It expects to raise about $38.6 million from the IPO after discounts and expenses are deducted. It said it will use the proceeds of the offering to hire sales and marketing staff and cover increased marketing costs, fund components of its Vantera testing system and develop new tests for it, and pay dividends on preferred stock.
The underwriters of the offering will have the option to buy another 750,000 shares over the next month to cover any over allotments.
The stock is listed on the Nasdaq Global Market Friday under the ticker symbol "LPDX."
(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)